Tag Archive: Acclarent Inc.

Off-label marketing leads to $18M settlement

Author: admin August 16, 2016

The Department of Justice (“DOJ”) recently announced a settlement with Johnson & Johnson subsidiary Acclarent Inc. over allegations of off-label marketing.  The DOJ’s suit alleged that Acclarent caused false claims to be submitted to the government in conjunction with the…
Read more

Healthcare Fraud, medical fraud, Medicare, Qui Tam, Whistleblower award

Acclarent Inc., Department of Justice, DOJ, False Claims Act, FCA, FDA, Johnson & Johnson, off-label marketing, Qui tam, U.S. Food and Drug Administration